Esmya® is approved in the European Union for long-term management of symptomatic uterine fibroids1.
- Esmya® (Ulipristal acetate 5mg) is now indicated for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age7.
- The efficacy and safety of intermittent treatment with Esmya® has been confirmed in the recent PEARL III extension and PEARL IV studies 7,44.
- Esmya® is effective for bleeding control and reduction in fibroid volume7.
- Efficacy of Esmya® is maintained even during off-treatment periods and is well tolerated7.